Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 4:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 565 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: IMRT Clear all
Completed Phase 2 Interventional Results available

Randomized Trial of Suicide Gene Therapy and Prostate Cancer

NCT00583492
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ad5-yCD/mutTKSR39rep-ADP, IMRT
Biological · Radiation
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 18, 2026, 4:15 AM EDT
Active, not recruiting Phase 2 Interventional

Radiation Therapy in Treating Women With Early Stage Breast Cancer

NCT00909909
View directory record Official record
Conditions
Breast Cancer
Interventions
External beam boost, whole breast irradiation
Radiation
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2027
U.S. locations
4
States / cities
Hamilton, New Jersey • New Brunswick, New Jersey • Somerset, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Oct 18, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

Glioblastoma Multiforme (GBM) Proton vs. Intensity Modulated Radiotherapy (IMRT)

NCT01854554
View directory record Official record
Conditions
Brain Cancer
Interventions
IMPT, IMRT, Cognitive Tests, Questionnaires
Radiation · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 18, 2026, 4:15 AM EDT
Terminated Phase 3 Interventional Results available

Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)

NCT02952586
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Avelumab, Chemoradiation
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
697 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
139
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 91 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 18, 2026, 4:15 AM EDT
Terminated Phase 1Phase 2 Interventional

Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer

NCT01693276
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Abraxane, Radiation Therapy
Drug · Radiation
Lead sponsor
Olugbenga Olowokure
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 26, 2015 · Synced Oct 18, 2026, 4:15 AM EDT
Not listed Phase 3 Interventional Results available

Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer

NCT00807768
View directory record Official record
Conditions
Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Fatigue, Neurotoxicity Syndrome, Obesity, Stage I Uterine Corpus Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7
Interventions
3-Dimensional Conformal Radiation Therapy, Carboplatin, Intensity-Modulated Radiation Therapy, Internal Radiation Therapy, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
Radiation · Drug · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
533
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 352 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 18, 2026, 4:15 AM EDT
Terminated No phase listed Observational

QOL & Functional Outcomes After Combined Modality Tx for Anal CA: Comparison of Conventional vs IMRT

NCT00568425
View directory record Official record
Conditions
Anal Cancer
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
30 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Oct 18, 2026, 4:15 AM EDT
Terminated Phase 1 Interventional Results available

Phase I Study of Intensity Modulated Radiation Therapy for Prostate Cancer

NCT00124917
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation
Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 90 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2019 · Synced Oct 18, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer

NCT03796767
View directory record Official record
Conditions
Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Oligometastasis, Prostate Adenocarcinoma, PSA Failure
Interventions
Hypofractionated Radiation Therapy, Intensity-Modulated Radiation Therapy, Metastasectomy, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Radiation · Procedure · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 18, 2026, 4:15 AM EDT
Recruiting Not applicable Interventional

Tongue-out Radiation Therapy (TORT) for the Mitigation of Radiotherapy-related Toxicities in Patients With Head and Neck Cancer

NCT07227792
View directory record Official record
Conditions
Head and Neck Carcinoma
Interventions
Tongue-out radiation therapy (TORT)
Radiation
Lead sponsor
Yvonne Mowery
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 18, 2026, 4:15 AM EDT
Not listed Phase 1Phase 2 Interventional

Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery

NCT00275067
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
arsenic trioxide, temozolomide, radiation therapy
Drug · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2021
U.S. locations
3
States / cities
Chicago, Illinois • Naperville, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 18, 2026, 4:15 AM EDT
Active, not recruiting Phase 2 Interventional

Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

NCT04675710
View directory record Official record
Conditions
Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Squamous Cell Carcinoma
Interventions
Conventional Surgery, Dabrafenib, Intensity-Modulated Radiation Therapy, Pembrolizumab, Quality-of-Life Assessment, Trametinib
Procedure · Drug · Radiation + 2 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
6
States / cities
Stanford, California • Ann Arbor, Michigan • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 18, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy With or Without Chemotherapy in Reducing Mouth Dryness in Patients With Nasopharyngeal Cancer

NCT00057785
View directory record Official record
Conditions
Head and Neck Cancer, Oral Complications of Radiation Therapy, Radiation Toxicity
Interventions
cisplatin, fluorouracil, Intensity modulated radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
17
States / cities
Birmingham, Alabama • Davis, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 18, 2026, 4:15 AM EDT
Completed Phase 1Phase 2 Interventional

Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

NCT00662506
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
Interventions
Cediranib Maleate, Diffusion Tensor Imaging, Diffusion Weighted Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Fludeoxyglucose F-18, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Perfusion Magnetic Resonance Imaging, Positron Emission Tomography, Temozolomide
Drug · Procedure · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Oct 18, 2026, 4:15 AM EDT
Terminated Phase 2 Interventional Results available

GTX-RT in Borderline Resectable Pancreatic Cancer

NCT01754623
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Capecitabine, Gemcitabine, Docetaxel, Stereotactic body radiation therapy (SBRT), Restaging review after radiation, Surgery, 5-Fluorouracil
Drug · Radiation · Other + 1 more
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Oct 18, 2026, 4:15 AM EDT
Not yet recruiting Phase 3 Interventional

Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall

NCT07823491
View directory record Official record
Conditions
Resectable Liposarcoma, Resectable Soft Tissue Sarcoma, Resectable Undifferentiated Pleomorphic Sarcoma
Interventions
Biospecimen Collection, Computed Tomography, Doxorubicin, Ifosfamide, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pembrolizumab, Questionnaire Administration, Surgical Procedure, Transthoracic Echocardiography Test
Procedure · Drug · Radiation + 2 more
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 18, 2026, 4:15 AM EDT
Terminated Phase 2 Interventional Results available

Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

NCT01822496
View directory record Official record
Conditions
Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7
Interventions
Radiation Therapy, Carboplatin, Cisplatin, Crizotinib, Erlotinib, Etoposide, Paclitaxel
Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
174
States / cities
Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 137 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Oct 18, 2026, 4:15 AM EDT
Active, not recruiting Not applicable Interventional

Quarterback 2b - Sequential Therapy With Reduced Dose Chemoradiotherapy for HPV Oropharynx Cancer

NCT02945631
View directory record Official record
Conditions
Locally Advanced HPV Positive Oropharynx Cancer
Interventions
PTV56, PTV50.4
Radiation
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 18, 2026, 4:15 AM EDT
Terminated Not applicable Interventional Results available

Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer

NCT01367301
View directory record Official record
Conditions
Stage IA Uterine Sarcoma, Stage IB Uterine Sarcoma, Stage IC Uterine Sarcoma, Stage IIA Uterine Sarcoma, Stage IIB Uterine Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma, Stage IIIC Uterine Sarcoma, Stage IVA Uterine Sarcoma, Stage IVB Uterine Sarcoma, Uterine Carcinosarcoma
Interventions
paclitaxel, carboplatin, external beam radiation therapy, brachytherapy, intensity-modulated radiation therapy, laboratory biomarker analysis
Drug · Radiation · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 18, 2026, 4:15 AM EDT
Recruiting Phase 1 Interventional

Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)

NCT05371132
View directory record Official record
Conditions
Metastatic Malignant Solid Neoplasm, Lymphoma
Interventions
Positron Emission Tomography, Stereotactic Body Radiation Therapy, Zirconium Zr 89-Df-Crefmirlimab, Intensity Modulated Radiation Therapy
Procedure · Radiation · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 18, 2026, 4:15 AM EDT
Completed Phase 2 Interventional

Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT)

NCT00855647
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Hypo-fractionated Radiotherapy
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Male only
Enrollment
99,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2010 · Synced Oct 18, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

Treatment De-Intensification for Squamous Cell Carcinoma of the Oropharynx

NCT01088802
View directory record Official record
Conditions
Squamous Cell Carcinoma of Oropharynx
Interventions
IMRT, Cisplatin, Carboplatin
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 18, 2026, 4:15 AM EDT
Suspended Phase 1 Interventional

68Ga-Dotatate PET and MRI Guided Radiation Dose Escalation for High Risk Meningioma

NCT07353229
View directory record Official record
Conditions
High Risk Meningioma, Recurrent Meningioma
Interventions
⁶⁸Ga-Dotatate PET and MRI Guided Radiation Therapy, Magnetic Resonance Imaging (MRI), 68Ga-Dotatate PET Imaging, MD Anderson Symptom Inventory Bain Tumor form (MDASI-BT), EuroQol-5 Dimension (ED-5D)
Radiation · Diagnostic Test · Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 18, 2026, 4:15 AM EDT
Completed Phase 1 Interventional

Radiotherapy to the Prostate and Dominant Intra-Prostatic Lesion (DIL)

NCT03269422
View directory record Official record
Conditions
Prostate Cancer
Interventions
MR-based image-guided, intensity-modulated radiotherapy
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 18, 2026, 4:15 AM EDT